1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  05/18 11:36:31 am EDT
10216.00 GBX   -2.59%
08:48aKepler Cheuvreux Downgrades AstraZeneca to Hold From Buy
MT
07:52aKepler Cheuvreux Drops AstraZeneca To Hold From Buy, Lifts PT
MT
04:59aAstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU warns not enough COVID vaccines for all in Europe until 2022

10/27/2020 | 11:36am EDT
FILE PHOTO: A woman holds a small bottle labeled with a

BRUSSELS (Reuters) - Only part of the European Union population can be inoculated against the new coronavirus before 2022, EU officials said in an internal meeting, as the vaccines the bloc is securing may not prove effective or may not be manufactured in sufficient doses.

The 27-nation bloc, with a population of 450 million, has booked more than 1 billion doses of potential COVID-19 vaccines from three drugmakers. It is negotiating the advance purchase of another billion vials with other companies.

"There will not be sufficient doses of COVID-19 vaccines for the entire population before the end of 2021," a European Commission official told diplomats from EU states in a closed-door meeting on Monday, a person who attended it told Reuters.

A second official confirmed the statement. An EU Commission spokesman was not immediately available for comment.

The EU Commission had earlier said vaccines will be limited "during the initial stages of deployment" but had never clarified how long the initial phase would last.

There is still no effective COVID-19 vaccine, but the first shots could be available at the beginning of next year, the Commission said earlier in October.

Given a likely limited supply, the Commission has for months urged EU governments to devise vaccination plans that would prioritise vulnerable and essential groups, such as healthcare workers, the elderly or people with chronic diseases.

But apart from a consensus on inoculating doctors and nurses, "there is no common line on other groups," the Commission official said at the internal meeting this week.

In July a paper agreed by the Commission and EU governments said at least 40% of the EU population should be vaccinated in the first phase.

Some EU countries want to book doses for their entire population with the aim of rolling them out already by mid-2021.

A third EU official said this bold goal could be achieved if the EU reached supply deals with at least seven vaccine candidates.

The EU has so far secured doses of the potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson. It has also said it is in talks with Moderna, Pfizer and CureVac.

(Reporting by Francesco Guarascio @fraguarascio, Editing by William Maclean and Alexandra Hudson)

By Francesco Guarascio


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.59% 10216 Delayed Quote.20.86%
MODERNA, INC. -3.21% 137.71 Delayed Quote.-43.98%
PFIZER, INC. -1.83% 50.4 Delayed Quote.-13.06%
SANOFI 1.00% 100.92 Real-time Quote.12.80%
All news about ASTRAZENECA PLC
08:48aKepler Cheuvreux Downgrades AstraZeneca to Hold From Buy
MT
07:52aKepler Cheuvreux Drops AstraZeneca To Hold From Buy, Lifts PT
MT
04:59aAstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies aga..
AQ
03:01aFrom storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17What you need to know about the coronavirus right now
RE
05/17ASTRAZENECA : Deutsche Bank keeps its Buy rating
MD
05/17AstraZeneca Obtains Exclusive Global License To Develop Antibodies Against COVID-19
MT
05/17FTSE 100 lags European peers on strong pound
RE
05/17RQ Biotechnology Ltd Signs Licensing Agreement with AstraZeneca PLC
CI
05/16AstraZeneca Expands License Deal With Drug Discovery Startup to Develop Cancer Therapie..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 739 M - -
Net income 2022 5 294 M - -
Net Debt 2022 22 519 M - -
P/E ratio 2022 37,2x
Yield 2022 2,32%
Capitalization 197 B 197 B -
EV / Sales 2022 5,02x
EV / Sales 2023 4,60x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 127,07 $
Average target price 143,18 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.86%202 631
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868